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Abstract: Psoriasis is a common, chronic, inﬂ  ammatory skin disease that can have a signiﬁ  cant 
impact on the quality of life of those who are afﬂ  icted. Recent advances in the understanding 
of the pathophysiology of psoriasis have led to the development of new, genetically engineered, 
targeted therapies for this disease. Among the most successful strategies for treatment has been 
the use of biologic immunotherapies targeting tumor necrosis factor alpha (TNF). Recent research 
has evaluated the efﬁ  cacy and safety of a new anti-TNF agent, adalimumab. Adalimumab is a 
human monoclonal antibody that is approved by the US Food and Drug Administration (FDA) 
and the European Medicines Agency (EMEA) for the treatment of rheumatoid arthritis and 
psoriatic arthritis. Recently released data from large, randomized clinical trials suggests that 
adalimumab has signiﬁ  cant efﬁ  cacy for the treatment of chronic plaque psoriasis and is well 
tolerated. Thus, adalimumab seems to be a promising therapeutic approach for patients who 
suffer from moderate to severe plaque psoriasis.
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Psoriasis is a chronic, inﬂ  ammatory disease that affects approximately 2%–3% of 
the world’s population. To date, this immune-mediated disease is incurable, and most 
commonly manifests itself as plaque-type psoriasis, which is characterized by the 
presence of red, thick, scaly lesions. It is an emotionally and physically debilitating 
disease that has a signiﬁ  cantly negative impact on an affected person’s quality of life 
(Krueger et al 2001). In the effort to improve treatment for patients who suffer from 
this disease, research has led to the discovery of several new therapies that directly 
target against the immune response that drives psoriasis. One speciﬁ  c protein that has 
proven as an effective target for therapy is tumor necrosis factor-alpha (TNF-α). This 
article will provide a brief overview of current available biologic agents that target 
TNF-α in treatment of psoriasis, with particular emphasis on the human monoclonal 
antibody, adalimumab.
Psoriasis and immunity
Psoriasis is an example of an immune mediated disease. The interaction of multiple 
immune cell types including T-cells, macrophages, and dendritic cells induces abnor-
mally rapid keratinocytic proliferation and incomplete maturation. These abnormalities 
result in thickening and scaling of the skin, the primary hallmarks of psoriasis.
One of the central immunological mediators in psoriasis is the cytokine TNF-α. It 
is one of the major naturally occurring cytokines in the skin, and is involved in several 
normal and abnormal inﬂ  ammatory immune responses, and is found in elevated levels 
in the skin of psoriatic patients (Rau 2002). TNF-α directly effects the pathogenesis of 
psoriasis, and demonstrates this by inducing the synthesis of adhesion molecules on 
endothelial cells and keratinocytes. This process thereby inﬂ  uences cellular inﬁ  ltra-
tion in the skin, and has a direct effect on the abnormal keratinoctye proliferation and 
maturation seen in psoriatic lesions (Gottlieb 2003).Therapeutics and Clinical Risk Management 2008:4(2) 346
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Current methods of treatment: 
biologic agents
Traditional treatments for moderate to severe psoriatic disease 
include phototherapy, systemic retinoids, methotrexate, and 
cyclosporine. However, as our understanding of the immuno-
pathogenesis of psoriasis evolves, new directions in treatment 
of this disease have shifted to include newer biological agents 
that target speciﬁ  c immune cells and molecules, such as those 
responsible for the proliferation of keratinocytic changes seen 
in plaque psoriasis. Biological agents are proteins derived 
from recombinant DNA technology, hybridomas, blood, and 
whole human cells. In psoriasis, these agents are designed to 
speciﬁ  cally interfere with inﬂ  ammatory cell activation. Some 
of these drugs, particularly those that target TNF-α, are also 
effective in treating psoriatic arthritis (PsA) (Winterﬁ  eld 
et al 2005).
There are several treatment methods available to block 
the induction or maintenance of T cell activation in psoriatic 
disease. One method that has proven successful involves 
inactivation of secreted effector cytokines. TNF-α appears 
to be a critical cytokine for many of the clinical features of 
psoriasis, including keratinocyte hyperproliferation, endo-
thelial cell regulation, and recruitment/effector function of 
memory T cells (Winterﬁ  eld et al 2005). Several anti-TNF 
drugs, such as etanercept, inﬂ  iximab, and adalimumab, have 
been used successfully to treat psoriasis and PsA.
Anti-TNF therapies
Etanercept was the first drug approved by the US Food 
and Drug Administration (FDA) for the treatment of 
cutaneous psoriasis, and is administered twice weekly by 
subcutaneous injection. It is a fusion protein composed 
of human TNF type II receptor (TNF-Rp75) and human 
IgG1 Fc Region, which binds to soluble TNF-α (Papp 
2006). In clinical trials, etanercept administered at a dose 
of 25 mg subcutaneously twice weekly demonstrated 
statistically significant Psoriasis Area and Severity Index 
(PASI) 75 results (defined as a 75% improvement from 
baseline) of 30%–34% at 12 weeks and 44%–56% at 24 
weeks (Gottlieb et al 2003; Leonardi et al 2003). Greater 
efficacy was achieved using doses of 50 mg subcutane-
ously twice weekly, resulting in PASI 75 responses of 
49% at 12 weeks and 59% at 24 weeks (Moreland et al 
2002). As with other anti-TNF drugs, risk of infection 
is a concern when using etanercept. In controlled trials, 
the rates of infections were not different from those in 
patients treated with placebo or methotrexate (Moreland 
et al 2002; Mease et al 2000; Gaylor and Duvic 2004). 
However, it should be noted that post-marketing safety 
surveillance has included reports of serious and, rarely, 
fatal infections in patients treated with anti-TNF agents 
(Winterfield et al 2005).
Inﬂ  iximab, an FDA-approved drug for the treatment 
of severe psoriasis, was the ﬁ  rst TNF blocker studied for 
the treatment of psoriasis. It is a chimeric monoclonal 
antibody that binds soluble and membrane-bound TNF-
α that is administered by intravenous infusion. Phase II 
trials studying inﬂ  iximab demonstrated the efﬁ  cacy of 
this medication for the treatment of psoriasis (Chaudhari 
et al 2001; Gottlieb et al 2004). A phase III, international, 
multi-center, randomized, placebo-controlled trial of adult 
patients with plaque psoriasis was performed to validate 
the results of the phase II program (Reich et al 2005). The 
study demonstrated that nearly 80% of subjects randomized 
to the inﬂ  iximab arm achieved PASI 75 through 24 weeks 
of therapy (Moreland et al 2002). Since inﬂ  iximab is a 
chimeric antibody, there is the potential for development 
of neutralizing antibodies (Winterﬁ  eld et al 2004). In the 
phase III trial, infection rates were comparable between the 
treated and placebo groups and post marketing data from 
inﬂ  iximab-treated patients with RA, Crohn’s disease, or 
other indications for which inﬂ  iximab is approved suggest 
a potential increased risk for events such as opportunistic 
infections (eg, tuberculosis), lymphoma, or congestive 
heart failure (Reich et al 2005).
Figure 1 Percentage of patients achieving 75% improvement in Psoriasis Area and 
Severity Index response at week 12 in the phase II and phase III trials. Because the 
phase II trial did not have week 16 data (the primary endpoint for the phase III 
trials), we compared the week 12 PASI 75 for all three clinical trials.
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Role of adalimumab in treatment 
of psoriasis
Adalimumab is currently FDA and European Medicines 
Agency (EMEA) approved for treatment of PsA and rheuma-
toid arthritis, for which it is administered every other week 
by subcutaneous injection. It is a recombinant, fully human 
Immunoglobulin G1 monoclonal antibody that binds with 
high afﬁ  nity and speciﬁ  city to TNF-α (Calabrese 2003). It 
consists of 1330 amino acids and has a molecular weight of 
approximately 148 kDa (Krueger et al 2000). Once it is given, 
the drug reaches it peak level at 5½ days, with a half-life of 
approximately 14 days (den Broeder et al 2002). The majority 
of responses attributed to TNF are regulated by the p55 cell 
surface TNF receptors. Upon binding to TNF-α, adalimumab 
blocks its interaction with the p55 and p75 cell surface TNF 
receptors. Adalimumab works by altering TNF-induced or 
regulated biological responses, such as changes in the levels 
of adhesion molecules responsible for leukocyte migration 
(Abbott Laboratories 2004). This process of neutralization 
of TNF-α by a speciﬁ  c monoclonal antibody should improve 
both skin and joint manifestations of psoriasis.
Efﬁ  cacy of adalimumab
The efﬁ  cacy of adalimumab has been studied in phase II and 
phase III clinical trials for the treatment of moderate to severe 
plaque-type psoriasis. The data are summarized in Figure 1. 
The ﬁ  rst data were provided by the phase II, double-blind, 
placebo-controlled, randomized trial evaluating 147 subjects 
with psoriatic involvement of at least 5% of their body surface 
area (BSA) and a minimum PASI score of at least 10 (Gordon 
et al 1998). This dose-ﬁ  nding trial evaluated adalimumab as 
monotherapy without the addition of other systemic therapies, 
topical medication, or light therapy. The primary endpoint of the 
study was the percentage of subjects achieving at least a PASI 
75 score at week 12. After week 12, subjects were followed 
and provided treatment for an additional 48 weeks through 
week 60. During the ﬁ  rst 12 weeks, patients were randomized 
into one of three groups: 1) Placebo, 2) Low dose group 
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Figure 2 Clinical and histological response of subject in phase II study of adalimumab after 12 weeks. Clinical photos target lesion at day 0 (A) and day 84 (B) and repre-
sentative histological specimens at day 0 (C) and day 84 (D).Therapeutics and Clinical Risk Management 2008:4(2) 348
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–80 mg loading dose for 1 week, followed by 40 mg every 
other week (eow), or 3) High dose group –80 mg loading dose 
for 2 weeks, followed by 40 mg every week (ew). After week 
12, subjects in the placebo arm were crossed over to receive 
the eow regimen, while all other subjects continued on their 
prior dosing schedule. At the week 24 endpoint, subjects on 
the eow arm with disease recurrence up to 50% of their initial 
PASI (PASI 50) were permitted to dose escalate to 40 mg 
weekly. Data were analyzed as a non-responder imputation 
(NRI) analysis, with any patient requiring dose escalation 
considered a treatment failure (Gordon et al 1998).
The results of this phase II study demonstrated the efﬁ  cacy 
of adalimumab in the treatment of moderate to severe plaque-
type psoriasis. In this trial, the primary endpoint of PASI 75 or 
better was achieved in 53% and 80% of the patients receiving 
adalimumab eow or every week, respectively, as compared 
to 4% of the patients receiving placebo. At week 60, 56% of 
the eow group achieved PASI 75, as compared to 64% for the 
weekly group (Gordon et al 1998). Data of particular interest 
included a PASI 100 (total clearance of psoriasis) at week 
60 in 16% of subjects in the low dose group (eow) and 26% 
of subjects in the high dose group (ew) (Gordon et al 1998). 
Additionally, clinically and statistically signiﬁ  cant improve-
ments in the Dermatology Life Quality Index (DLQI) were 
reported at week 60 (Shikiar et al 2006). Clinical and histologi-
cal responses of a typical patient are shown in Figure 2.
Two phase III trials were devised to provide a greater 
body of data to validate the successful results of the initial 
phase II study. The ﬁ  rst was a 16-week study performed in 
Europe and Canada, comparing the efﬁ  cacy of adalimumab 
to methotrexate and placebo. The second study, conducted 
in North America, compared adalimumab monotherapy to 
placebo for longer term use (Menter et al 2007).
The comparator phase III trial was the ﬁ  rst study to 
directly compare the clinical efﬁ  cacy, safety, and toler-
ability of any biologic to a traditional systemic agent in the 
treatment of moderate to severe chronic plaque psoriasis 
(Saurat et al 2006). In this study, 271 subjects were ran-
domized in a 2:2:1 ratio into one of three arms: 1) 80 mg 
loading dose for 1 week, followed by 40 mg every other 
week (eow) for the next 15 weeks, 2) methotrexate under 
a published regimen (Roenigk et al 1998), or 3) placebo. 
The main inclusion for participation included a clinical 
diagnosis of plaque- type psoriasis for at least 12 months, 
an affected BSA of at least 10%, and a PASI score of 10 or 
greater. The primary endpoint of the trial was the percent-
age of subjects achieving a PASI 75 response rate at week 
16 (Saurat et al 2006).
The results of the comparator study established that 
adalimumab provided signiﬁ  cantly greater efﬁ  cacy in the 
treatment of moderate to severe plaque- type psoriasis versus 
metho-trexate and versus placebo. The primary endpoint 
(PASI 75) was demonstrated in 80% of subjects in the 
adalimumab group, as compared to 36% in the methotrexate 
group, and 19% in the placebo group. A Physician Global 
Assessment (PGA) score of “clear” or “minimal” was achieved 
in 73% of the adalimumab treated patients versus 30% in the 
methotrexate group and 11% in placebo (Saurat et al 2006).
While this trial successfully established the relative 
efﬁ  cacy of adalimumab in comparison to methotrexate in the 
treatment of plaque- type psoriasis, there are some difﬁ  cul-
ties that should be mentioned. The achieved placebo control 
rate of PASI 75 was abnormally high at 19%. However, an 
analysis of the treatment effect, a measure that subtracts for 
the placebo rate from the overall response, is 62%, compa-
rable to other trials with adalimumab (Menter et al 2007). 
Furthermore, although this study used a published protocol 
for methotrexate dosing, it has been argued that the metho-
trexate response would be higher with a more aggressive 
treatment regimen. However, it is important to acknowledge 
that a more aggressive approach may also result in greater rate 
of hepatic abnormalities (Heydendael et al 2003). Since the 
data analysis of this protocol was a non-responder imputation 
(NRI) analysis, it is not certain that a higher methotrexate 
dose would give a greater response rate. Therefore, it is valid 
to conclude that adalimumab showed signiﬁ  cant efﬁ  cacy 
advantages over methotrexate in this trial.
The North American phase III trial examined the short 
and long term efﬁ  cacy of adalimumab as monotherapy versus 
placebo. This 52-week, randomized, double-blind, placebo-
controlled, multicenter, phase III study evaluated 1,212 
patients with moderate to severe chronic plaque psoriasis, 
deﬁ  ned a PASI  12 and BSA  10% (Menter et al 2007). 
There were two independent primary endpoints in this trial. 
The ﬁ  rst primary endpoint was the proportion of patients that 
achieved PASI  75 at week 16. The second primary endpoint 
was the percentage of patients losing an adequate response 
(deﬁ  ned as PASI  50 or a 6 point increase in PASI score) 
between weeks 33 and 52 (Menter et al 2007). The study 
was divided into three treatment periods (A, B, and C), and 
PASI 50/75/90/100 and PGA results were evaluated using 
non-responder imputation (NRI) analysis (Menter et al 2007). 
In the double-blind, placebo-controlled period A, patients 
were randomized 2:1 to receive 80 mg of adalimumab at 
baseline (week 0) followed by 40 mg eow, or placebo through 
week 15. At week 16, patients with PASI  75 entered period Therapeutics and Clinical Risk Management 2008:4(2) 349
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B, at which point they would receive adalimumab 40 mg 
eow from weeks 17 to 33. Patients who did not achieve PASI 
75 at week 16 were enrolled into the open label extension 
(OLE) study. At week 33, patients who achieved PASI  75 
continued onto the double-blind, placebo-controlled period C 
and are re-randomized, 1:1 to receive adalimumab or placebo 
(Menter et al 2007). Loss of adequate response in this group 
is compared between weeks 33 and 52. Partial responders 
(PASI 50   75) at week 33 were enrolled into the OLE 
study, and patients who were non-responders (PASI  50) 
at week 33 were discontinued from the study (Menter et al 
2007). Patients originally randomized in period A to receive 
placebo and achieved PASI  75 at week 16, continued to 
receive adalimumab therapy in period C if they achieved 
PASI  75 in period B.
The ﬁ  rst primary endpoint measured after 16 weeks of 
therapy, patients receiving adalimumab responded to their 
treatment at signiﬁ  cantly higher rates than their placebo 
counterparts. Results from short-term therapy demonstrated 
that approximately 71% of patients achieved at least a 75% 
improvement of their psoriasis. Of interest, the mean percent-
age PASI improvement as compared to baseline was main-
tained at roughly 90%, and nearly 23% of patients pooled 
from period B and the OLE study achieved 100% clearance 
of their psoriasis through 24 weeks of therapy (Menter et al 
2007). In the second primary endpoint measured at week 52, 
period C, 5% of patients receiving adalimumab experienced 
a loss of adequate response, signiﬁ  cantly lower than the 28% 
of patients who were randomized to receive placebo during 
the same period.
The results of the phase III adalimumab monotherapy 
trial effectively demonstrates that treatment with adalimumab 
40 mg eow is highly efﬁ  cacious for patients with moderate 
to severe plaque-type psoriasis. The study conﬁ  rms that 
adalimumab’s efﬁ  cacy is sustainable as evidenced in the 
open label extension study, and discontinuation of adalim-
umab therapy is associated with loss of adequate response 
(Menter et al 2007).
Adalimumab may also be effective in patients who are 
refractory to other systemic agents. A small trial of 9 psoriatic 
patients who failed previous anti-TNF therapies found that 
adalimumab was an effective treatment for their psoriasis with 
62.5% reaching a PASI 75 in 20 weeks (Pitarch et al 2007).
Safety and tolerability 
of adalimumab
Adalimumab was well tolerated in both phase II and III 
studies. In the phase II trial, the most reported adverse event 
was pain with injection, especially in the high dose group. 
Other adverse events were similar to placebo, with headache, 
nausea, elevated triglycerides, cough, sinus congestion, and 
fatigue most common. Two cancers were noted, however, 
review of patient histories determined that both cancers 
were likely present upon entry into the study (Gordon et al 
1998). There were an increased number of serious adverse 
events (SAEs) in the highest dosing group in the phase II 
trial. However, this increase in SAEs was not observed in 
either the initial phase III trial, or the long-term phase III trial 
(Menter et al 2007). In the phase III comparator study, there 
were no signiﬁ  cant differences in the incidences of adverse 
events reported for adalimumab-treated versus methotrexate-
treated and placebo-treated patients, and the most frequent 
adverse events reported were nasopharyngitis and headache 
(Saurat et al 2006).
The safety proﬁ  le observed in the phase III adalimumab 
monotherapy trial is consistent with earlier studies. In ini-
tial 16-week double-blind, placebo-controlled portion of 
the trial, period A, the percentage of patients and rates of 
AEs and infectious AEs were greater in the adalimumab 
group as compared to the placebo group; however, less than 
1% of the infectious AEs were considered serious (Menter 
et al 2007). The percentage of SAEs and serious infectious 
AEs in the adalimumab-treated group during period A was 
comparable to the rates experienced by the placebo group. 
During the ﬁ  rst 16 weeks, a greater percentage of patients 
withdrawing study participation occurred in the placebo-arm 
experiencing AEs than in the adalimumab-treated group 
(Menter et al 2007). Additionally, the 52-week safety proﬁ  le 
conﬁ  rmed that the rates of SAEs, serious infectious AEs, 
and malignancies among adalimumab-treated patients were 
low and comparable to those patients in the placebo-arm in 
period A (Menter et al 2007). The most common side effects 
experienced by patients in the adalimumab treatment arm 
were upper respiratory infections (7.2%), nasopharyngitis 
(5.3%), headache (4.9%), and injection site reactions (3.1%) 
(Menter et al 2007).
To achieve a greater understanding of the safety and toler-
ability of adalimumab, it is helpful to review the data from 
clinical studies and post-marketing observations of the drug 
in the treatment of rheumatoid arthritis (RA). It is impor-
tant to point out, however, that the RA patient population 
is typically quite different than that of psoriasis, as the RA 
population tends to be older and on other immunosuppressive 
agents, including methotrexate and systemic corticosteroids. 
With this in mind, there is still much that can be learned from 
the RA trials regarding the safety of adalimumab.Therapeutics and Clinical Risk Management 2008:4(2) 350
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Adalimumab’s mechanism of action may suppress the 
human body’s defenses against infections and malignancies, and 
therefore these risks are the greatest concern when using this 
type of medication. In randomized, placebo-controlled RA trials, 
the risk of serious infection is comparable, or slightly increased 
between groups treated with adalimumab and those on placebo 
when controlled for exposure duration (Furst et al 2003; Schiff 
et al 2006). Furthermore, the rate of serious infections seems to 
be most dependent upon the age of the patient and on the con-
cominant use of systemic corticosteroids and/or methotrexate 
(Kent et al 2006; Schiff et al 2006). In another trial, the rates of 
infection were higher in methotrexate monotherapy as compared 
to monotherapy adalimumab, but the rates of infection were even 
greater when the two medications were combined (Breedveld 
et al 2006). These results indicate that risk of infection with 
adalimumab may be lower in younger psoriasis patients who are 
being treated with monotherapy (Winterﬁ  eld et al 2005).
The possibility of reactivation of latent tuberculosis (Tb) 
is an area of concern with the arrival of anti-TNF-α biologic 
therapies. In clinical trials with adalimumab, there were thir-
teen reported cases of Tb (Abbott Laboratories 2004). While 
cases of Tb were reported among all doses, the incidence was 
greatest at doses of adalimumab that were higher than the 
recommended dose (Abbott Laboratories 2004). Appropriate 
screening for Tb is important, as it can reduce the incidence 
of reactivation of Tb by 82% (Perez et al 2006).
Other than infection, cancer was the greatest concern of 
safety raised in the RA trials using adalimumab. Meta-analysis 
suggested that the incidence of solid tumors when evaluated 
without regard to critical values like duration of study period, 
was higher in adalimumab treated patients. However, when the 
data are normalized for length of follow-up, the data suggest that 
there is no noticeable increase in risk of cancer for RA patients 
on adalimumab as compared to what is observed in the general 
population (Schiff et al 2006). Similarly, the rate of lymphoma 
is what would be expected in RA patients being treated with 
adalimumab, although this rate is higher than the general 
population (Schiff et al 2006). Other potential side effects of 
adalimumab use in the RA population include demyelinating 
disease, worsening of congestive heart failure, and clinically 
apparent autoimmunity (Abbott Laboratories 2004).
One of the largest studies looking at the tolerability, effec-
tiveness, and safety of adalimumab was a multi-center, open 
label clinical study with 6610 rheumatoid arthritis patients 
treated with adalimumab alone or in combination with standard 
disease-modifying antirheumatic drugs (DMARDs). The most 
notable serious adverse events observed in patients receiving 
adalimumab monotherapy were serious infections (1.7%). 
Rare SAEs such as malignancy (0.65%), congestive heart 
failure (0.3%), demyelinating disease (0.06%), and systemic 
lupus erythematosus (0.03%) were observed among the 6610 
patients receiving adalimumab monotherapy and adalimumab 
plus DMARDs (including methotrexate). Table 1 summarizes 
the serious adverse events captured in this trial (Burmester et al 
2007). Although these events are extremely rare, clinicians 
should use caution when using adalimumab therapy.
Conclusion
Psoriasis is a chronic and debilitating inﬂ  ammatory skin 
disease that affects a signiﬁ  cant proportion of the population. 
The advent of biologic agents, and speciﬁ  cally anti-TNF-α 
therapy, has provided clinicians with promising new treatment 
options for their patients’ moderate to severe psoriatic disease. 
In clinical trials, adalimumab has demonstrated excellent 
efﬁ  cacy in the treatment of more severe cases of psoriasis. 
Additionally, research subjects tolerated adalimumab quite 
well, and reported signiﬁ  cant improvement in their quality of 
life. While more clinical data are needed to fully understand 
the risk associated with adalimumab use in psoriasis, current 
information demonstrates that this medication is an appropri-
ate option for treatment of moderate to severe psoriasis.
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